Adoptive cell therapy, including Chimeric antigen receptor T-cell (CAR-T) therapy targeting HER2 (90), NK cells and tumor-infiltrating lymphocytes (TILs) enhances anti-tumor immunity by overcoming immune escape (91, 92). The gene discussed is ERBB2; the disease is neoplasm.